Protagonist Therapeutics PTGX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -192.4%— | -343.6%— | 9.1%— | —— | —— | |
| Net margin | -154.9%— | -282.8%— | 21.9%— | —— | —— | |
| Returns | ||||||
| Return on equity | -17.1%— | -20.2%— | 7.8%— | —— | —— | |
| Return on invested capital | -27.6%— | -29.1%— | 3.8%— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.1×-0.2× | 0.1×-0.7× | 0.3×-0.4× | 0.3×-0.4× | 0.3×-0.4× | |
| Liquidity | ||||||
| Current ratio | 17.8×+0.5× | 12.7×+0.2× | 13×+2.4× | 17×+3.2× | 17.3×+1.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $9.30-15.0% | $9.67-6.8% | $10.12+17.5% | $10.52+19.1% | $10.94+24.2% | |
| Valuation | ||||||
| Market capitalization | $6.73B+127% | $5.46B+137% | $4.13B+49.8% | $3.33B+57.8% | $2.97B+68.6% | |
| Price / sales | 90.8×+76.5× | 118.7×+113× | 19.8×+11.2× | 15.9×— | 14.3×— | |
| Price / book | 10.3×+6.0× | 8.9×+5.5× | 6.4×+1.2× | 5×+1.1× | 4.3×+1.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Protagonist Therapeutics's ratios come from?
- Every ratio is computed from Protagonist Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
